Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349694 | 0.87 | BRD4 (0.40) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL1348736 | 0.87 | BRD4 (0.40) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL20569604 | 0.85 | KDM4E (0.53) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL1348700 | 0.83 | ATP1A1 (0.42) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| Efetozole SCHEMBL2109012 | 0.79 | BRD4 (0.51) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| Efetozole SCHEMBL21698044 | 0.79 | BRD4 (0.51) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| Efetozole SCHEMBL10996922 | 0.77 | BRD4 (0.50) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL28780266 | 0.77 | ALDH1A1 (0.47) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL27762347 | 0.77 | ALDH1A1 (0.47) | MEN1HPGDKMT2AHSD17B10KDM4E | |
| SCHEMBL27881082 | 0.77 | MEN1 (0.47) | MEN1HPGDKMT2AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | claimed |
| EP-2139489-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008118319-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063090-B2 | Mineralocorticoid receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| EP-2139489-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118319-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118319-A2 | MINERALOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069452-A1 | MINERALOCORTICOID RECEPTOR MODULATORS | NR3C2, MC2R, NR3C1 | MEN1 1380/4885HPGD 490/4885KMT2A 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.